Company / Capital Expenditures
NeoGenomics Laboratories, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$27.0M
FY2025
5-year range
$27.0M / $64.1M
FY2021-FY2025
Trend
-34.2%
vs FY2024
Sector context
#98 of 151
Health Care
What the data says
At $27M, NeoGenomics Laboratories, Inc.'s capital expenditures ranks #98 of 151 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $8M in FY2016 to $64M in FY2021.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of -1.5%.
Declined from $29M to $27M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -4.4%
- 5-Year CAGR
- -1.5%
- 10-Year CAGR
- -
Sector benchmark
#98 of 151 in Health CareTop 65% of 151This company $27.0M Sector average $271.7M
▼
-90.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.5%, indicating a declining trend.
- In FY2025, capital expenditures decreased 34.2% year-over-year.
- Ranks #98 out of 151 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.0M | -34.2% |
| FY2024 | $41.1M | +42.8% |
| FY2023 | $28.8M | -6.9% |
| FY2022 | $30.9M | -51.8% |
| FY2021 | $64.1M | +120.4% |
| FY2020 | $29.1M | +45.3% |
| FY2019 | $20.0M | +40.0% |
| FY2018 | $14.3M | +4.5% |
| FY2017 | $13.7M | +81.7% |
| FY2016 | $7.5M | +240.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026